Core Viewpoint - The company, Shuanglu Pharmaceutical, confirmed its normal operational status and ongoing business activities, including recent acquisitions in the healthcare sector [1] Group 1: Company Operations - Shuanglu Pharmaceutical's main business activities include technology development, consulting, transfer, and hospital management [1] - The company has acquired Jinmei General Hospital (a tertiary hospital) and several secondary and primary hospitals, as well as community health service stations through its subsidiary, Shanxi Jinmei Guoke New Mile Medical Management Co., Ltd [1] - The company stated that it is currently in a normal operational phase, with all situations being normal [1]

Core Viewpoint - The company, Shuanglu Pharmaceutical, announced on September 1 that it will disclose changes in the number of shareholders in its regular reports, with a total of 58,492 shareholders as of June 30, 2025 [1] Summary by Category - Shareholder Information - As of June 30, 2025, the total number of shareholders for the company is reported to be 58,492 [1] - Reporting Practices - The company will provide updates on shareholder changes in its periodic reports [1]

Group 1 - The company, Shuanglu Pharmaceutical, is currently conducting supplementary research on its short-acting follicle-stimulating hormone (FSH) and plans to reapply for approval after the research is completed [1] - The long-acting recombinant human follicle-stimulating hormone (FSH-CTP) has already submitted its application for market approval [1]

Group 1 - The company, Shuanglu Pharmaceutical, stated on September 1 that Dapagliflozin is currently not listed on the network, and any updates will be communicated in a timely manner [2]

Group 1 - The company, Shuanglu Pharmaceutical, is committed to enhancing its e-commerce platform development [2]

Group 1 - The core viewpoint is that not all generic drugs are in highly competitive categories, and there are distinctions in quality among them [2] - The pharmaceutical market in China is expected to primarily focus on generic drugs due to its status as a developing country [2] - The company has been increasing its focus on innovative drugs and biopharmaceuticals for the past five years, with plans for new innovative product submissions in the future [2]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问公司有布局溶瘤病毒产品的研发吗？研发进度情 况如何？ 双鹭药业（002038.SZ）9月1日在投资者互动平台表示，公司暂没有布局相关领域。 ...

Group 1 - The core issue raised by investors concerns the patent status of Dulaglutide and the delay in its submission for approval [2] - The company, Donglu Pharmaceutical, clarified on September 1 that there are no patent issues with its GLP-1 long-acting formulation and that it is currently preparing the necessary documentation for submission [2] - The specific timeline for the submission remains uncertain as the company is still in the process of gathering materials [2]

Core Viewpoint - The company has developed DT678 tablets, a globally innovative drug for anti-platelet aggregation, which is currently in Phase II clinical trials and shows superior efficacy compared to Clopidogrel with fewer side effects [1][3]. Group 1 - DT678 tablets are a co-development between the company and DT Company, which is partially owned by the University of Michigan, with the company holding a 30% stake in DT Company [1][3]. - The company possesses exclusive rights for the development and use of the patented compound in China [1][3]. - Preliminary results from Phase I trials indicate that DT678 has over 20 times the efficacy of Clopidogrel, with advantages such as rapid onset, fewer side effects, and greater stability [3].

Group 1 - The core viewpoint of the article is that institutional investors have increased their holdings in Shuanglu Pharmaceutical, with a total of 1.88 billion shares held, representing 18.33% of the company's total equity as of August 26, 2025 [1] - The proportion of institutional holdings has risen by 0.42 percentage points compared to the previous quarter [1] - Among public funds, only one fund, the Southern CSI 1000 ETF, increased its holdings, with an increase ratio of 0.12% [1] Group 2 - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.23% compared to the previous period [1] - A total of six institutional investors are reported to hold shares in Shuanglu Pharmaceutical [1] - New institutional investors include the Southern CSI 1000 ETF and Haitong Zhixuan B, which were newly disclosed in this period [1]